

**National Advisory Committee on Immunization (NACI) Summary of Discussion
October 1-2, 2014 meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Opening Remarks	<p>The Chair, Dr. Ian Gemmill, welcomed participants to the meeting. The Chair introduced a new liaison representative, Dr. Catherine Mah from the Canadian Public Health Association, and two new ex-officio representatives from Health Canada, Dr. Jim Gallivan from Marketed Health Products Directorate and Dr. Gina Coleman from Biologics and Genetic Therapies Directorate.</p> <p>Dr. John Spika, Director General, Centre for Immunization and Respiratory Infectious Diseases acknowledged the appointment of Dr. Gregory Taylor as the new Chief Public Health Officer. Dr Spika also informed NACI members that Dr. Caroline Quach-Thanh will be the incoming NACI Vice-Chair, with her two year term beginning immediately following the meeting.</p> <p>NACI's 50th anniversary was acknowledged as well as the important role it has played in Canada since 1964.</p>
Prevalence of HPV genotypes in HPV-related cancers and cervical pre-cancers in Canada and overview of 9-valent (9vHPV) vaccine program – key results	<p>The presentation by Merck assessed the current evidence on the prevalence of HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58 genotypes in Canada for HPV-related cancers as well as cervical precancerous lesions. The investigational 9-valent HPV VLP vaccine (9vHPV) includes the 4 HPV types (6, 11, 16, 18) in the 4vHPV vaccine and 5 additional oncogenic types (31, 33, 45, 52, 58). The 9vHPV vaccine has the potential to broaden protection for cervical cancer and precancers, as well as for other HPV-related cancers and precancers. An overview of the 9vHPV vaccine clinical development program and results from the clinical trials were provided.</p>
Statement: Human Papillomavirus 2-dose Schedule	<p>An update of the progress to date and draft recommendations were provided to NACI. NACI approved the recommendations with minor edits. Final Chair approval to be sought following the meeting.</p>

**National Advisory Committee on Immunization (NACI) Summary of Discussion
October 1-2, 2014 meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Statement on Seasonal Influenza Vaccine for 2015-16	<p>The Influenza Working Group Chair gave a brief description of the agenda item. The following presentations were provided to NACI for consideration in the 2015-16 influenza vaccine statement, as appropriate.</p> <ul style="list-style-type: none"> • Findings of a literature review on Pediatric Fluad® Influenza Vaccine Use in Children 6-72 Months of Age. • Findings of a literature review on Fluzone® High-Dose vaccine. • A review of evidence on reduced immunogenic responses in young children, 6-72 months, as a potential factor related to differences in product use. <p>Following the presentations, the new format for 2015-16, combining the Canadian Immunization Guide Chapter on Influenza and the annual statement on seasonal influenza vaccine was presented.</p>
Concomitant Administration of Live Vaccines	<p>NACI members discussed the current recommendation for LAIV administration with other live vaccines and decided that a review of the evidence should be conducted to inform a future committee discussion. An ad-hoc working group is to be established to complete the evidence review and present the findings to NACI.</p>
Risk of febrile seizures following MMRV	<p>A review of the current NACI recommendations and a recent evidence review were presented to NACI. A draft statement update will be completed with the NACI Vaccine Safety and other relevant working groups for further review and consideration by NACI during the February meeting.</p>
Varicella vaccination: Validity of self-reported history of disease as proof of immunity	<p>This item was a follow-up to a presentation and discussion held at the NACI June 2014 meeting. NACI members discussed key issues including timing of self-report and health care workers and setting, followed by a review of draft recommendations. A revised statement update to be brought back to NACI for review and discussion during the February meeting.</p>

**National Advisory Committee on Immunization (NACI) Summary of Discussion
October 1-2, 2014 meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Statements: Hepatitis A and B	The Hepatitis A & B Working Group provided an overview of their activities from May to September 2014, including proposed next steps. Five issues were discussed by the working group; the off label use of the Hepatitis A vaccine in infants 6-11 months, the need for / timing of a Hepatitis B (HB) booster in adolescents vaccinated in infancy, the need for a Hepatitis B booster in immunocompromised persons, the risk of Hepatitis B infection in diabetics, and the timing and indications of HBIg. An update and presentation of draft items, if available, will be provided to NACI during the February meeting.
Statement: Varicella Immune Globulin (Varlg) Update	Current NACI recommendations were reviewed as well as draft text for a statement update for an expanded time period for post-exposure management in susceptible persons; 10 days versus 96 hours in the current recommendations. The draft recommendations and statement update will be presented to NACI for final approval either before or during the February meeting.
Statement: Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23)	Recommendations in the Pneu-P-23 statement, approved by NACI in July 2014, were reviewed and confirmed by NACI. The statement will be submitted for the Chair's final approval following the meeting.
ACIP PCV13 Recommendation for all adults ≥65 years of age	NACI discussed the ACIP approved PCV13 recommendations for all adults ≥65 years of age, which were voted on during an ad-hoc meeting in August 2014. The initiation of a NACI work plan item to be further discussed with the Pneumococcal Working Group.

**National Advisory Committee on Immunization (NACI) Summary of Discussion
October 1-2, 2014 meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
<p>Liaison and Ex-officio Representative Updates</p>	<p>The following liaison and ex-officio representatives provided updates from their host organization, if available.</p> <p><u>Liaison Representatives:</u> Association of Medical Microbiology and Infectious Disease Canada (AMMI); Canadian Association for Immunization Research and Evaluation (CAIRE); Canadian Immunization Committee; Canadian Paediatric Society (CPS); Canadian Public Health Association (CPHA); Centers for Disease Control and Prevention (CDC); College of Family Physicians of Canada (CFPC); Council of Chief Medical Officers of Health (CCMOH); and Society of Obstetricians and Gynaecologists of Canada (SOGC).</p> <p><u>Ex-officio Representatives:</u> Biologics and Genetic Therapies Directorate (BGTD), Health Canada; Marketed Health Products Directorate, Health Canada; National Defence and the Canadian Armed Forces; Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada.</p>
<p>Canadian Immunization Guide (the Guide)</p>	<p>An update was provided on the Guide review process and revisions in progress. Feedback was sought from NACI on a proposed review schedule, 2014 to 2018, based on comments received at the NACI June 2014 meeting.</p>
<p>Canadian Communicable Disease Report (CCDR) Canadian Immunization Guide (the Guide) Commentary</p>	<p>A CCDR commentary was published in April 2014 to inform readers of key changes in Part 4 of the Guide, Active Vaccines. NACI agreed that this would be a useful knowledge translation tool going forward to inform readers of future changes in the Guide.</p>
<p>Vaccine Safety Working Group Update</p>	<p>The working group chair provided an update on their activities, including discussion and review of evidence on rotavirus and influenza vaccination and the collection of data on vaccine administration errors.</p>

**National Advisory Committee on Immunization (NACI) Summary of Discussion
October 1-2, 2014 meeting, Ottawa, Ontario**

AGENDA ITEM	SUMMARY
Tdap discussion on question regarding vaccination of medical students	PHAC received an inquiry pertaining to the vaccination of medical school students, seeking clarification on the current Tdap recommendations in the Guide. This issue was discussed at the June meeting and brought back to NACI for further discussion and decision. NACI confirmed the interpretation of the recommendations in the Guide; young adult health care workers should be vaccinated when starting clinical work if they have not previously received Tdap in adulthood, regardless of when Tdap was given in adolescence. NACI also noted that there is a need to review the evidence on the timing of the adolescent booster dose at a future meeting.
General NACI Business	NACI members were provided with a status update on current activities / timelines. NACI members also discussed the committee's work plan item list and future priorities.
National Immunization Strategy (NIS)	The Associate Director General, Centre for Immunization and Respiratory Infectious Diseases provided an update on the Public Health Review of the NIS.